TABLE 3.
SHR2285 Pharmacokinetic parameters.
| Treatment (SHR2285) | |||
|---|---|---|---|
| Group A n = 12 | Group B n = 13 | Group C n = 12 | |
| Cmax, ng/mL | 3,780 (28.8) | 6,020 (36.7) | 7,290 (16.1) |
| Tmax, h | 1.5 (1.5–2.5) | 1.5 (1.5–2.0) | 1.5 (1.5–2.0) |
| AUCtau, h*ng/mL | 14,300 (26.4) | 19,700 (33.7) | 25,200 (22.9) |
| AUC0-last, h*ng/mL | 19,400 (32.5) | 28,100 (31.0) | 33,800 (21.5) |
| AUC0-inf, h*ng/mL | 19,600 (33.0) | 29,500 (27.5) | 34,900 (24.9) |
| t1/2, h | 13.9 (5.56) | 14.5 (5.43) | 13.8 (7.02) |
| CLss/F, L/h | 14.8 (3.68) | 15.7 (4.15) | 12.2 (2.75) |
| Vss/F, L | 283 (87.8) | 343 (213) | 227 (76.4) |
| Ctrough, ng/mL | 337 (43.9) | 501 (40.1) | 505 (29.1) |
| Caverage, ng/mL | 1,190 (26.4) | 1,650 (33.7) | 2,100 (22.9) |
Cmax, AUCtau, AUC0-last and AUC0-inf are presented as geometric mean (GCV), Tmax as median (range), t1/2, CLss/F and Vss/F as mean (standard deviation).
GCV, geometric coefficient of variation; Cmax, maximum concentration; Tmax, time to reach maximum concentration; AUCtau, area under the plasma concentration-time curveat steady-state (one dose interval); AUC0-last, area under the plasma concentration-time curve from time 0 to last time of quantifiable concentration; AUC0-inf, area under the plasma concentration-time curve from time 0 extrapolated to infinite time; t1/2, elimination half-life; CLss/F, steady state clearance rate of oral administration; Vss/F, apparent volume of distribution; Ctrough, valley concentration; Caverage, steady-state average concentration.